Latest News

Friday, July 21, 2017 | FDA Approval/Clearance, Imaging & Testing

FDA Clears First MRI System for Neonatal Brain Imaging

The FDA cleared the Embrace Neonatal MRI System, the first of its of its king specifically for neonatal brain and head imaging in neonatal intensive care units (NICU). The Embrace Neonatal MRI System …

Read the full story

Wednesday, July 19, 2017 | Product Launches and Updates

CSL Behring: FDA Accepts sBLA for Hizentra® for Chronic Inflammatory Demyelinating Polyneuropathy

The FDA has accepted for review CSL Behring’s supplemental Biologics License Application (BLA) for Hizentra®([Immune globulin subcutaneous [Human] 20% liquid) for the treatment for…

Read the full story

Monday, July 17, 2017 | Dementia & Cognitive Disorders

AAIC 2017: Electronic Self-Administered Test Performs Similarly to Pen-and-Paper Version in Detecting MCI and Early Dementias

Findings presented at the Alzheimer’s Association International Conference in London indicate that the self-administered eSAGE (BrainTest Inc.) test performs similar to its validated pen-an…

Read the full story

Monday, July 17, 2017 | Dementia & Cognitive Disorders, Research and Publications

AAIC 2017: Healthy Diets Tied to Decreased Likelihood of Cognitive Impairment In Older Individuals

The benefits of a healthy diet may extend to cognitive health, according to findings presented at the Alzheimer’s Association International Conference in London. Among nearly 6,000 older adults …

Read the full story

Thursday, July 13, 2017 | Movement Disorders

Sage Bionetworks Launches DREAM Challenge to Identify Best Uses for Remote Sensing Devices

Sage Bionetworks has launched the Parkinson’s Disease Digital Biomarker DREAM Challenge, the first in a series of open, crowd-sourced analytical projects to help researchers identify ways to use…

Read the full story

Wednesday, July 12, 2017 | Movement Disorders, Research and Publications

Visual System Changes May Represent an Early Signal of Parkinson’s Disease

Changes in the intracranial visual system may be a signal of Parkinson’s disease (PD), according to new findings published in Radiology. Using MRI, researchers evaluated 21 patients with newly d…

Read the full story

Thursday, July 06, 2017 | Dementia & Cognitive Disorders, Research and Publications, Sleep

Sleep Disturbances Linked to Alzheimer’s Disease

Poor sleep may be a sign that otherwise healthy individuals may have an increased risk of developing Alzheimer’s disease later in life over those who do not have sleep problems, according to a s…

Read the full story

Friday, June 30, 2017 | Epilepsy & Seizure Disorders, Product Launches and Updates

VNS Therapy Approved in Children Ages Four Years and Older with Partial Onset Refractory Seizures

The FDA has approved the VNS Therapy (LivaNova) in patients as young as four years of age with partial onset refractory seizures. Originally approved for patients ages 12 years and older, VNS The…

Read the full story

Tuesday, June 27, 2017 | Dementia & Cognitive Disorders

Phase 3 Results Suggest Promise of Investigational Alzheimer’s Agent in Mild Disease

New Phase 3 findings published in the Journal of the Prevention of Alzheimer’s Disease show that Alzheon’s investigational agent tramiprosate (ALZ-801) may offer cognitive and functional b…

Read the full story

Tuesday, June 27, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials

Low-Dose Fenfluramine Granted Orphan Status for LGS

The FDA has granted orphan drug designation to ZX008 (Zogenix), an investigational treatment for Lennox Gastaut Syndrome (LGS). Zogenix will initiate a Phase 3 clinical trial in LGS in second half of …

Read the full story

Thursday, June 22, 2017 | Stroke & Cerebrovascular, Visual & Sensory Disturbances

Dysport Approved for Lower Limb Spasticity

The FDA has expanded the indication of Dysport (abobotulinumtoxinA, Ipsen Biopharmaceuticals) to include lower limb spasticity. In a Phase 3 study, adult patients treated with Dysport following a stro…

Read the full story

Wednesday, June 14, 2017 | Movement Disorders, Phase 3/4 Trials, Research and Publications

Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment

Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (L…

Read the full story

Tuesday, June 13, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days

New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a s…

Read the full story

Monday, June 12, 2017 | Epilepsy & Seizure Disorders

American Epilepsy Society Awards Investigators for Early Career Research

The American Epilepsy Society (AES) has awarded 25 early career scientists and clinicians with fellowships or grants to support their work in epilepsy research. The award recipients include pre-doctor…

Read the full story

Friday, June 09, 2017 | Movement Disorders, Research and Publications

Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT

PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presente…

Read the full story
Load More